Search

Your search keyword '"Lies Hulshof"' showing total 6 results
Start Over Author "Lies Hulshof"
6 results on '"Lies Hulshof"'

1. Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis

Author

Lies Hulshof, Saskia A. Overbeek, Anne L. Wyllie, Mei Ling J. N. Chu, Debby Bogaert, Wilco de Jager, Leon M. J. Knippels, Elisabeth A. M. Sanders, Wim M. C. van Aalderen, Johan Garssen, Belinda van’t Land, Aline B. Sprikkelman, The Clinical Study Group, A. Blauw, B. Dontje, Y. C. M. Duijvestein, W. H. C. de Boom, I. Groot, M. Boks, Y. van Kooyk, D. H. H. Fandri, D. Hijnen, M. A. Middelkamp-Hup, B. Papi, M. Roelofs, A. Rijnierse, D. Veening, Clinical Trial Support, B. J. Prakken, G. W. Ten Tusscher, R. A. Tupker, and L. E. M. Willemsen

Subjects
atopic dermatitis, atopic dermatitis severity, chemokine profiles, dietary intervention, infants, T helper cell type 2/T helper cell type 1 response, Immunologic diseases. Allergy, RC581-607
Abstract

BackgroundAtopic dermatitis (AD) is the most common chronic inflammatory skin disease in infancy with a complex pathology. In adults, the clinical severity of AD has been associated with increases in T helper cell type (Th) 2, Th22, and Th17 serum markers, including high levels of CC chemokine ligand (CCL) 17 and CCL22 chemokines.ObjectiveTo explore the possible association between serum chemokine levels and AD severity in infants with moderate-to-severe AD and elevated immunoglobulin E (IgE).Subjects and methodsSerum samples (n = 41) obtained from a randomized, double-blind, and clinical dietary intervention study were used to study biomarkers in infants with AD. Baseline- and post-intervention samples (4 months) were used, six chemokines and nine ratios thereof were analyzed using Luminex and correlated to AD severity. In the initial study, the infants were randomized to receive extensively hydrolyzed whey-based formula without (control) or with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).Results31 Infants up to 11 months of age, with an objective-SCORAD score (oSCORAD) ≥ 20 and elevated total-IgE and/or specific-IgE levels were included. In time, the median oSCORAD decreased in both groups by −8 (control, p

Published
2018
Full Text
View/download PDF

2. Prevalence and early-life risk factors of school age allergic multimorbidity - the EuroPrevall-iFAAM birth cohort

Author

Sigridur Erla Sigurdardottir, Kristján Jónasson, Montserrat Fernandez Rivas, Paraskevi Xepapadaki, Graham Roberts, Santiago Quirce, Marek L. Kowalski, Marcin Kurowiski, Songül Yürek, Andreas Reich, Kate Grimshaw, Philip Couch, Aline B. Sprikkelman, Odilija Rudzeviciene, Nikolaos G. Papadopoulos, Lies Hulshof, Johanna Bellach, Michael Clausen, Ana Fiandor, Linus Grabenhenrich, Kirsten Beyer, Sigurveig T. Sigurdardottir, Kristin Lilja Bjornsdottir, Ruta Dubakiene, Thomas Keil, Ronald van Ree, Sina Maria Erhard, Clare Mills, Graduate School, General Paediatrics, AII - Inflammatory diseases, Ear, Nose and Throat, Experimental Immunology, APH - Global Health, APH - Personalized Medicine, and Groningen Research Institute for Asthma and COPD (GRIAC)

Subjects
Male, 0301 basic medicine, Allergy, Pediatrics, CHILDREN, Cohort Studies, 0302 clinical medicine, Pregnancy, Risk Factors, Surveys and Questionnaires, Prevalence, Immunology and Allergy, Prospective Studies, MATERNAL SMOKING, Child, education.field_of_study, Schools, 3. Good health, SENSITIZATION, Cohort, Original Article, Female, eczema, medicine.medical_specialty, Immunology, Population, ECZEMA, 03 medical and health sciences, children, medicine, Humans, Medical history, EXPOSURE, Epidemiology and Genetics, education, Asthma, allergic rhinitis, business.industry, Infant, Newborn, Multimorbidity, RHINITIS, Odds ratio, NATURAL-HISTORY, asthma, medicine.disease, Rhinitis, Allergic, Comorbidity, RHINOCONJUNCTIVITIS, 030104 developmental biology, 030228 respiratory system, allergic multimorbidity, Observational study, ORIGINAL ARTICLES, business, COMORBIDITY
Abstract

Background Coexistence of childhood asthma, eczema and allergic rhinitis is higher than can be expected by chance, suggesting a common mechanism. Data on allergic multimorbidity from a pan‐European, population‐based birth cohort study have been lacking. This study compares the prevalence and early‐life risk factors of these diseases in European primary school children. Methods In the prospective multicentre observational EuroPrevall‐iFAAM birth cohort study, we used standardized questionnaires on sociodemographics, medical history, parental allergies and lifestyle, and environmental exposures at birth, 12 and 24 months. At primary school age, parents answered ISAAC‐based questions on current asthma, rhinitis and eczema. Allergic multimorbidity was defined as the coexistence of at least two of these. Results From 10,563 children recruited at birth in 8 study centres, we included data from 5,572 children (mean age 8.2 years; 51.8% boys). Prevalence estimates were as follows: asthma, 8.1%; allergic rhinitis, 13.3%; and eczema, 12.0%. Allergic multimorbidity was seen in 7.0% of the whole cohort, ranging from 1.2% (Athens, Greece) to 10.9% (Madrid, Spain). Risk factors for allergic multimorbidity, identified with AICc, included family‐allergy‐score, odds ratio (OR) 1.50 (95% CI 1.32–1.70) per standard deviation; early‐life allergy symptoms, OR 2.72 (2.34–3.16) for each symptom; and caesarean birth, OR 1.35 (1.04–1.76). Female gender, OR 0.72 (0.58–0.90); older siblings, OR 0.79 (0.63–0.99); and day care, OR 0.81 (0.63–1.06) were protective factors. Conclusion Allergic multimorbidity should be regarded as an important chronic childhood disease in Europe. Some of the associated early‐life factors are modifiable and may be considered for prevention strategies., Allergic multimorbidity (coexistence of asthma, eczema and allergic rhinitis) is common among European children at primary school age, with 7% of study participants affected. Protective factors identified in the study include female sex, having older siblings and attending day care. Risk factors include history of allergic diseases in first‐degree family members, early‐age symptoms and caesarean birth.

Published
2021
Full Text
View/download PDF

3. A minimally invasive tool to study immune response and skin barrier in children with atopic dermatitis

Author

Christoph Riethmüller, B. van't Land, D.P. Hack, Q.C.J. Hasnoe, Bianca Dontje, Alida Sprikkelman, M.A. Middelkamp‐Hup, W.M.C. van Aalderen, Lies Hulshof, Sanja Kezic, Ivone Jakasa, Whi McLean, Groningen Research Institute for Asthma and COPD (GRIAC), Paediatric Pulmonology, AII - Inflammatory diseases, Coronel Institute of Occupational Health, APH - Personalized Medicine, APH - Societal Participation & Health, General Paediatrics, Dermatology, APH - Quality of Care, CCA - Cancer Treatment and Quality of Life, and APH - Methodology

Subjects
Male, Chemokine, atopic dermatitis, stratum corneum analysis, biomarkers, children, natural moisturizing factor, skin barrier, skin type differences, Light skin, Dark skin, Skin Pigmentation, Dermatology, Filaggrin Proteins, Permeability, Dermatitis, Atopic, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Medicine, CCL17, CXCL10, Humans, Child, Corneocyte, biology, integumentary system, business.industry, S100 Proteins, Infant, Atopic dermatitis, medicine.disease, Case-Control Studies, Child, Preschool, Immunology, Mutation, biology.protein, Feasibility Studies, Female, Chemokines, Epidermis, business, CCL22, Biomarkers
Abstract

Background: Atopic dermatitis (AD) affects children of all skin types. Most research has focused on light skin types. Studies investigating biomarkers in people with AD with dark skin types are lacking. Objectives: To explore skin barrier and immune response biomarkers in stratum corneum (SC) tape strips from children with AD with different skin types. Methods: Tape strips were collected from lesional and nonlesional forearm skin of 53 children with AD and 50 controls. We analysed 28 immunomodulatory mediators, and natural moisturizing factors (NMF) and corneocyte morphology. Results: Interleukin (IL)-1β, IL-18, C-X-C motif chemokine (CXCL) 8 (CXCL8), C-C motif chemokine ligand (CCL) 22 (CCL22), CCL17, CXCL10 and CCL2 were significantly higher (P

Published
2019
Full Text
View/download PDF

5. Response to: Cost-effectiveness of using an extensively hydrolysed formula compared to an amino acid formula as first-line treatment for cow milk allergy in the UK

Author

W.M.C. van Aalderen, Niels W. Rutjes, I. de Vreede, Aline B. Sprikkelman, Lies Hulshof, Nicole C. M. Petrus, Paediatric Pulmonology, and Amsterdam institute for Infection and Immunity

Subjects
chemistry.chemical_classification, Food, Formulated, Male, Cost effectiveness, business.industry, Protein Hydrolysates, Immunology, Cow milk allergy, Carbohydrates, Dietary Fats, Infant Formula, Amino acid, First line treatment, Hydrolysis, chemistry, Pediatrics, Perinatology and Child Health, Immunology and Allergy, Medicine, Animals, Humans, Female, Food science, Amino Acids, Milk Hypersensitivity, business
Published
2012

6. Re: Oral desensitization as a useful treatment in 2-year-old children with cow's milk allergy

Author

Nicole C. M. Petrus, A. A. Schoemaker, Lies Hulshof, W.M.C. van Aalderen, and Aline B. Sprikkelman

Subjects
medicine.medical_specialty, Allergy, Cow's milk allergy, business.industry, medicine.medical_treatment, Immunology, medicine, Immunology and Allergy, business, medicine.disease, Dermatology, Desensitization (medicine)
Abstract

Cite this as: L. Hulshof, A. A. Schoemaker, N. C. M. Petrus, W. M. C. van Aalderen and A. B. Sprikkelman, Clinical & Experimental Allergy, 2011 (41) 1815-1816

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results